The closing price of Vir Biotechnology Inc (NASDAQ: VIR) was $9.62 for the day, down -5.69% from the previous closing price of $10.20. On the day, 999238 shares were traded. VIR stock price reached its highest trading level at $9.93 during the session, while it also had its lowest trading level at $9.60.
Ratios:
Our analysis of VIR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.05 and its Current Ratio is at 9.05. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’24 when HANLY ANN M. sold 2,711 shares for $10.05 per share. The transaction valued at 27,251 led to the insider holds 132,069 shares of the business.
Lee Sung sold 6,008 shares of VIR for $59,404 on Mar 27 ’24. The EVP & Chief Financial Officer now owns 100,492 shares after completing the transaction at $9.89 per share. On Feb 26 ’24, another insider, SCANGOS GEORGE A, who serves as the Director of the company, sold 17,722 shares for $11.65 each. As a result, the insider received 206,522 and left with 112,989 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 1.30B and an Enterprise Value of -100.21M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.07 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at -2.54 whereas that against EBITDA is 0.15.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $27.48, while it has fallen to a 52-week low of $7.72. The 50-Day Moving Average of the stock is 10.18, while the 200-Day Moving Average is calculated to be 11.94.
Shares Statistics:
VIR traded an average of 1.09M shares per day over the past three months and 813.47k shares per day over the past ten days. A total of 134.78M shares are outstanding, with a floating share count of 88.00M. Insiders hold about 34.83% of the company’s shares, while institutions hold 53.39% stake in the company. Shares short for VIR as of Mar 15, 2024 were 5.43M with a Short Ratio of 4.96, compared to 5.05M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.02% and a Short% of Float of 6.76%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$1.05 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.32, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.91 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$3.43 and -$4.94 for the fiscal current year, implying an average EPS of -$4.09. EPS for the following year is -$3.98, with 9 analysts recommending between -$2.83 and -$5.66.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $39.4M to a low estimate of $4.26M. As of the current estimate, Vir Biotechnology Inc’s year-ago sales were $50.1M, an estimated decrease of -76.10% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $9.35M, an increase of 146.20% over than the figure of -$76.10% in the same quarter last year. There is a high estimate of $21.3M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $22.69M, resulting in an average revenue estimate of $41.37M. In the same quarter a year ago, actual revenue was $86.18M, down -52.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $41.61M in the next fiscal year. The high estimate is $106.2M and the low estimate is $17.69M. The average revenue growth estimate for next year is up 0.60% from the average revenue estimate for this year.
